1
|
Sevillano D, Hervás A, Rodríguez-Patrón R, García-Fuentes J, Colmenares R, Vallejo C, López-Campos F, Domínguez-Rullán J, Muñoz T, Cámara M, Capuz B, Morís R, Galiano P, Retorta P, Williamson S, Béjar M, Prieto D, García-Vicente F. PD-0405 Analysis of the internal motion of the urethra caused by urethral catheters. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02840-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
2
|
Webb K, Cámara M, Zain N, Halliday N, Bruce K, Nash E, Whitehouse J, Knox A, Forrester D, Smyth A, Williams P, Fogarty A, Barr H. 446: Novel detection of specific bacterial quorum-sensing molecules in saliva: Potential noninvasive biomarkers for pulmonary Pseudomonas aeruginosa in cystic fibrosis. J Cyst Fibros 2021. [DOI: 10.1016/s1569-1993(21)01870-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
3
|
Orozco Martínez F, Morís R, Colmenares R, Cámara M, Capuz A, García J, Sevillano D, Retorta P, Béjar M, Prieto D, Galiano P, García F. PO-1769 Dosimetric consequences arising from beam interruptions with Catalyst – Deep inspiration breath hold. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)08220-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
4
|
Retorta P, Sevillano D, Cámara M, Capuz A, Colmenares R, García J, Morís R, Orozco F, Béjar M, Prieto D, Galiano P, García F. PO-1751 Inter- and intra-fractional uncertainties in deep inspiration breath-hold (DIBH) breast treatment. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)08202-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
5
|
Sevillano D, de la Pinta C, Fonseca A, Garcia-Fuentes J, Colmenares R, Capuz B, Morís R, Cámara M, Orozco F, Retorta P, Galiano P, Béjar M, Prieto D, García-Vicente F. PD-0780 Geometrical study of the feasibility of fiducial-less lymph node SBRT with Cyberknife. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07059-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
6
|
Sevillano D, García-Fuentes J, Cámara M, Fernández-Lizarbe E, Martín-Sánchez M, De la Pinta C, Colmenares R, Capuz B, Morís R, Orozco F, Retorta P, Galiano P, Béjar M, Prieto D, García-Vicente F. PO-1775 Effect of intra-fraction patient stability on treatment margins in brain SRS with Cyberknife. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)08226-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
7
|
Arbelo N, Sagué M, López-Pelayo H, Madero S, Pinzón-Espinosa J, Anmella G, Gomes-Da-Costa S, Ilzarbe L, Llach C, Cámara M, Imaz M, Pintor L. Psychiatric clinical profiles and pharmacological interactions in COVID-19 inpatients referred to a consultation liaison psychiatry unit. Eur Psychiatry 2021. [PMCID: PMC9470826 DOI: 10.1192/j.eurpsy.2021.290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Introduction The Coronavirus Disease 2019 (COVID-19) can affect mental health in different ways. There is little research about psychiatric complications in hospitalized patients with COVID-19. Objectives The aim of the study was to describe the psychiatric clinical profile and pharmacological interactions in COVID-19 inpatients referred to a Consultation-Liaison Psychiatry (CLP) unit. Methods This is a cross-sectional retrospective study, carried out at a tertiary hospital in Spain, in inpatients admitted because of COVID-19 and referred to our CLP Unit from March 17,2020 to April 28,2020. Clinical data were extracted from electronic medical records. The patients were divided in three groups depending on psychiatric diagnosis: delirium, severe mental illness (SMI) and non-severe mental illness (NSMI). Results Of 71 patients included (median [ICR] age 64 [54-73] years; 70.4% male), 35.2% had a delirium, 18.3% had a SMI, and 46.5% had a NSMI. Compared to patients with delirium and NSMI, patients with SMI were younger, more likely to be institutionalized and were administered less anti-COVID19 drugs. Mortality was higher among patients with delirium (21.7%) than those with SMI (0%) or NSMI (9.45%). The rate of side effects due to interactions between anti-COVID19 and psychiatric drugs was low, mainly drowsiness (4.3%) and borderline QTc prolongation (1.5%). Conclusions Patients affected by SMI were more often undertreated for COVID-19. However, the rate of interactions was very low, and avoidable with a proper evaluation and drug-dose adjustment. Half of the patients with SMI were institutionalized, suggesting that living conditions in residential facilities could make them more vulnerable to infection. Disclosure No significant relationships.
Collapse
|
8
|
Zain N, Webb K, Halliday N, Barrett D, Nash E, Whitehouse J, Honeybourne D, Smyth A, Forrester D, Dewar J, Knox A, Williams P, Fogarty A, Cámara M, Bruce K, Barr H. ePS6.04 2-Alkyl-4-quinolone quorum sensing signal molecules are potential biomarkers in cystic fibrosis pseudomonal infection. J Cyst Fibros 2020. [DOI: 10.1016/s1569-1993(20)30332-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
9
|
Gualpa J, Lopez G, Nievas S, Coniglio A, Halliday N, Cámara M, Cassán F. Azospirillum brasilense Az39, a model rhizobacterium with AHL quorum-quenching capacity. J Appl Microbiol 2019; 126:1850-1860. [PMID: 30924989 DOI: 10.1111/jam.14269] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2018] [Revised: 03/06/2019] [Accepted: 03/24/2019] [Indexed: 12/20/2022]
Abstract
AIMS The aim of this research was to analyse the quorum-sensing (QS) and quorum-quenching (QQ) mechanisms based on N-acyl-l-homoserine lactones (AHLs) in Azospirillum brasilense Az39, a strain with remarkable capacity to benefit a wide range of crops under agronomic conditions. METHODS AND RESULTS We performed an in silico and in vitro analysis of the quorum mechanisms in A. brasilense Az39. The results obtained in vitro using the reporter strains Chromobacterium violaceum and Agrobacterium tumefaciens and liquid chromatography coupled with mass-mass spectrometry analysis showed that although Az39 does not produce AHL molecules, it is capable of degrading them by at least two hypothetical enzymes identified by bioinformatics approach, associated with the bacterial cell. In Az39 cultures supplemented with 500 nmol l-1 of the C3 unsubstituted AHLs (C4, C6, C8, C10, C12, C14), AHL levels were lower than in noninoculated LB media controls. Similar results were observed upon the addition of AHLs with hydroxy (OH-) and keto (oxo-) substitutions in C3. These results not only demonstrate the ability of Az39 to degrade AHLs. They also show the wide spectrum of molecules that can be degraded by this bacterium. CONCLUSIONS Although A. brasilense Az39 is a silent bacterium unable to produce AHL signals, it is able to interrupt the communications between other bacteria and/or plants by a QQ activity. SIGNIFICANCE AND IMPACT OF THE STUDY This is the first report confirming by unequivocal methodology the ability of A. brasilense, one of the most agriculturally used benefic bacteria around the world, to degrade AHLs by a QQ mechanism.
Collapse
Affiliation(s)
- J Gualpa
- Laboratorio de Fisiología Vegetal y de la Interacción Planta-Microorganismo, Universidad Nacional de Río Cuarto, Córdoba, Argentina
| | - G Lopez
- Laboratorio de Fisiología Vegetal y de la Interacción Planta-Microorganismo, Universidad Nacional de Río Cuarto, Córdoba, Argentina
| | - S Nievas
- Laboratorio de Fisiología Vegetal y de la Interacción Planta-Microorganismo, Universidad Nacional de Río Cuarto, Córdoba, Argentina
| | - A Coniglio
- Laboratorio de Fisiología Vegetal y de la Interacción Planta-Microorganismo, Universidad Nacional de Río Cuarto, Córdoba, Argentina
| | - N Halliday
- Centre for Biomolecular Sciences, School of Life Sciences, University of Nottingham, Nottingham, UK
| | - M Cámara
- Centre for Biomolecular Sciences, School of Life Sciences, University of Nottingham, Nottingham, UK
| | - F Cassán
- Laboratorio de Fisiología Vegetal y de la Interacción Planta-Microorganismo, Universidad Nacional de Río Cuarto, Córdoba, Argentina
| |
Collapse
|
10
|
Sevillano D, Martín C, Vallejo C, Martín M, Colmenares R, Morís R, Capuz B, García J, Cámara M, Martínez A, Orozco F, Béjar M, Prieto D, Sancho S, García-Vicente F. EP-1899 Prediction of outcomes in lung SBRT with dosimetric variables and machine learning techniques. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)32319-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
11
|
Martín C, Sevillano D, Vallejo C, Martín M, García J, Colmenares R, Morís R, Capuz B, Cámara M, Martínez A, Orozco F, Béjar M, Prieto D, Sancho S, García-Vicente F. EP-1912 Outcome prediction with CT radiomics and random forests in primary lung tumor treated with SBRT. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)32332-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
12
|
Barr HL, Halliday N, Barrett DA, Williams P, Forrester DL, Peckham D, Williams K, Smyth AR, Honeybourne D, Whitehouse JL, Nash EF, Dewar J, Clayton A, Knox AJ, Cámara M, Fogarty AW. Diagnostic and prognostic significance of systemic alkyl quinolones for P. aeruginosa in cystic fibrosis: A longitudinal study; response to comments. J Cyst Fibros 2017; 16:e21. [PMID: 29079141 DOI: 10.1016/j.jcf.2017.09.008] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2017] [Accepted: 09/22/2017] [Indexed: 11/30/2022]
Affiliation(s)
- H L Barr
- Division of Respiratory Medicine, University of Nottingham, City Hospital Campus, Nottingham, UK.
| | - N Halliday
- School of Life Sciences, Centre for Biomolecular Sciences, University of Nottingham, Nottingham, UK
| | - D A Barrett
- Centre for Analytical Bioscience, School of Pharmacy, University of Nottingham, Nottingham, UK
| | - P Williams
- School of Life Sciences, Centre for Biomolecular Sciences, University of Nottingham, Nottingham, UK
| | - D L Forrester
- Division of Respiratory Medicine, University of Nottingham, City Hospital Campus, Nottingham, UK
| | - D Peckham
- Leeds Adult Cystic Fibrosis Centre, St James's University Hospital, Leeds, UK
| | - K Williams
- Leeds Adult Cystic Fibrosis Centre, St James's University Hospital, Leeds, UK
| | - A R Smyth
- Division of Child Health, Obstetrics and Gynaecology, University of Nottingham, UK
| | - D Honeybourne
- West Midlands Adult CF Centre, Heart of England, NHS Foundation Trust, Birmingham, UK
| | - J L Whitehouse
- West Midlands Adult CF Centre, Heart of England, NHS Foundation Trust, Birmingham, UK
| | - E F Nash
- West Midlands Adult CF Centre, Heart of England, NHS Foundation Trust, Birmingham, UK
| | - J Dewar
- Wolfson Cystic Fibrosis Centre, Department of Respiratory Medicine, Nottingham University Hospitals NHS Trust, Nottingham, UK
| | - A Clayton
- Wolfson Cystic Fibrosis Centre, Department of Respiratory Medicine, Nottingham University Hospitals NHS Trust, Nottingham, UK
| | - A J Knox
- Division of Respiratory Medicine, University of Nottingham, City Hospital Campus, Nottingham, UK
| | - M Cámara
- School of Life Sciences, Centre for Biomolecular Sciences, University of Nottingham, Nottingham, UK
| | - A W Fogarty
- Division of Epidemiology and Public Health, University of Nottingham, Clinical Sciences Building, University of Nottingham, Nottingham, UK
| |
Collapse
|
13
|
Ciruelos EM, Montaño Á, Rodríguez CA, González-Flores E, Lluch A, Garrigós L, Quiroga V, Antón A, Malón D, Chacón JI, Velasco M, Gonzalez-Cortijo L, Jolis L, Pascual T, Amigo Y, Casas M, Cámara MC, Carrasco E, Casas A. Abstract P4-21-16: Phase III trial to evaluate patient´s preference for subcutaneous versus intravenous trastuzumab administration in patients with HER2 positive advanced breast cancer (ABC) under IV trastuzumab (IV-t) treatment for at least 4 months. ChangHER-SC study (GEICAM/2012-07). Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-21-16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Patients with HER2-positive ABC, receive anti-HER2 treatment for several months or even years. IV-t is administered weekly or 3-weekly, mandating patients to visit the hospital on a regular basis to receive infusions. This has inconveniences for patients and increase treatment costs. Subcutaneous administration could improve convenience of trastuzumab therapy. This study was designed to evaluate patient's preference for IV-t or SC trastuzumab (SC-t) in ABC patients.
Methods:This is a phase III, open label, multicenter study inpatients with HER2 positive ABC, receiving IV-t for at least 4 months and without evidence of disease progression. Patients received 600 mg of SC-t, either from a vial or from a single injection device (SID), every 3 weeks for 4 cycles. Before starting SC-t, patients received an additional IV-t cycle. Patients were randomized 1:1 to arm A, receiving 2 cycles of SC-t with vial followed by 2 cycles with SID or arm B, receiving the opposite sequence. After cycle 4, patients decided to continue with IV-t or SC-t till disease progression. Stratification criteria were the associated therapy (Chemotherapy, Hormone-therapy or none) and its administration route (IV, oral or none). Patients completed a questionnaire of experiences and preferences at three time points: before starting SC-t, after cycle 2 and after cycle 4. Health Care Professionals completed a satisfaction questionnaire every 5 patients. The primary objective was to evaluate patient´s preference for IV-t or SC-t (after cycle 2) and, secondary objectives were, to evaluate patient´s preference between the two SC-t administrations (vial or SID) after cycle 4, Health Care Professional satisfaction, associated costs of the administration options (Time and Motion pharmacoeconomic study) and safety.
Results: From September-13 to July-15, 166 patients were randomized (81 arm A, 85 arm B) in 26 Spanish sites from GEICAM. Median age was 60 years (35-93), 88% of patients were postmenopausal and 123 and 42 had an ECOG PS of 0 and 1, respectively. The median duration of prior IV-t for ABC was 1.8 years (range: 0.3-14). Patients received a median of 2 previous lines of Chemotherapy and/or Hormone-therapy (range: 1-9). Twenty patients were receiving pertuzumab at inclusion. According to patient questionnaires completed after cycle 2, 137 patients preferred the SC-t (66 arm A, 71 arm B), 11 the IV-t (6 arm A, 5 arm B), 11 didn't have a preference (4 arm A, 7 arm B), and 7 didn't answer (3 progressed, 2 withdrew participation before cycle 2 and 2 unknown reason). Three of the 11 patients choosing IV-t were receiving IV treatment as accompanying therapy; after cycle 4 five of these 11 patients finally continued with SC-t, 5 with IV-t and 1 progressed. From the 11 patients without any preference 7 received SC-t, 2 receive IV-t and 2 progressed; from the 137 patients preferring SC-t, 125 actually received it, 3 received IV-t and 9 progressed.
Conclusions: Our study shows that 82.5% of patients preferred the SC-t over the IV-t. Treatment choice was not influenced by the accompanying therapy.
Citation Format: Ciruelos EM, Montaño Á, Rodríguez CA, González-Flores E, Lluch A, Garrigós L, Quiroga V, Antón A, Malón D, Chacón JI, Velasco M, Gonzalez-Cortijo L, Jolis L, Pascual T, Amigo Y, Casas M, Cámara MC, Carrasco E, Casas A. Phase III trial to evaluate patient´s preference for subcutaneous versus intravenous trastuzumab administration in patients with HER2 positive advanced breast cancer (ABC) under IV trastuzumab (IV-t) treatment for at least 4 months. ChangHER-SC study (GEICAM/2012-07) [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-21-16.
Collapse
Affiliation(s)
- EM Ciruelos
- Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Hospital Universitario de Salamanca-IBSAL, Zaragoza, Spain; Hospital Universitario Virgen de las Nieves, Granada, Spain; Hospital Clínico de Valencia, Instituto de Investigación Sanitaria INCLIVA, Universitat de València, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Institut Català d'Oncologia Badalona-HU Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; Hospital de Mataró (Consorci Sanitari del Maresme), Mataró, Barcelona, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital General de Granollers, Granollers, Barcelona, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain
| | - Á Montaño
- Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Hospital Universitario de Salamanca-IBSAL, Zaragoza, Spain; Hospital Universitario Virgen de las Nieves, Granada, Spain; Hospital Clínico de Valencia, Instituto de Investigación Sanitaria INCLIVA, Universitat de València, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Institut Català d'Oncologia Badalona-HU Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; Hospital de Mataró (Consorci Sanitari del Maresme), Mataró, Barcelona, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital General de Granollers, Granollers, Barcelona, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain
| | - CA Rodríguez
- Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Hospital Universitario de Salamanca-IBSAL, Zaragoza, Spain; Hospital Universitario Virgen de las Nieves, Granada, Spain; Hospital Clínico de Valencia, Instituto de Investigación Sanitaria INCLIVA, Universitat de València, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Institut Català d'Oncologia Badalona-HU Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; Hospital de Mataró (Consorci Sanitari del Maresme), Mataró, Barcelona, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital General de Granollers, Granollers, Barcelona, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain
| | - E González-Flores
- Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Hospital Universitario de Salamanca-IBSAL, Zaragoza, Spain; Hospital Universitario Virgen de las Nieves, Granada, Spain; Hospital Clínico de Valencia, Instituto de Investigación Sanitaria INCLIVA, Universitat de València, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Institut Català d'Oncologia Badalona-HU Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; Hospital de Mataró (Consorci Sanitari del Maresme), Mataró, Barcelona, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital General de Granollers, Granollers, Barcelona, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain
| | - A Lluch
- Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Hospital Universitario de Salamanca-IBSAL, Zaragoza, Spain; Hospital Universitario Virgen de las Nieves, Granada, Spain; Hospital Clínico de Valencia, Instituto de Investigación Sanitaria INCLIVA, Universitat de València, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Institut Català d'Oncologia Badalona-HU Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; Hospital de Mataró (Consorci Sanitari del Maresme), Mataró, Barcelona, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital General de Granollers, Granollers, Barcelona, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain
| | - L Garrigós
- Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Hospital Universitario de Salamanca-IBSAL, Zaragoza, Spain; Hospital Universitario Virgen de las Nieves, Granada, Spain; Hospital Clínico de Valencia, Instituto de Investigación Sanitaria INCLIVA, Universitat de València, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Institut Català d'Oncologia Badalona-HU Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; Hospital de Mataró (Consorci Sanitari del Maresme), Mataró, Barcelona, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital General de Granollers, Granollers, Barcelona, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain
| | - V Quiroga
- Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Hospital Universitario de Salamanca-IBSAL, Zaragoza, Spain; Hospital Universitario Virgen de las Nieves, Granada, Spain; Hospital Clínico de Valencia, Instituto de Investigación Sanitaria INCLIVA, Universitat de València, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Institut Català d'Oncologia Badalona-HU Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; Hospital de Mataró (Consorci Sanitari del Maresme), Mataró, Barcelona, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital General de Granollers, Granollers, Barcelona, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain
| | - A Antón
- Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Hospital Universitario de Salamanca-IBSAL, Zaragoza, Spain; Hospital Universitario Virgen de las Nieves, Granada, Spain; Hospital Clínico de Valencia, Instituto de Investigación Sanitaria INCLIVA, Universitat de València, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Institut Català d'Oncologia Badalona-HU Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; Hospital de Mataró (Consorci Sanitari del Maresme), Mataró, Barcelona, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital General de Granollers, Granollers, Barcelona, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain
| | - D Malón
- Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Hospital Universitario de Salamanca-IBSAL, Zaragoza, Spain; Hospital Universitario Virgen de las Nieves, Granada, Spain; Hospital Clínico de Valencia, Instituto de Investigación Sanitaria INCLIVA, Universitat de València, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Institut Català d'Oncologia Badalona-HU Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; Hospital de Mataró (Consorci Sanitari del Maresme), Mataró, Barcelona, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital General de Granollers, Granollers, Barcelona, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain
| | - JI Chacón
- Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Hospital Universitario de Salamanca-IBSAL, Zaragoza, Spain; Hospital Universitario Virgen de las Nieves, Granada, Spain; Hospital Clínico de Valencia, Instituto de Investigación Sanitaria INCLIVA, Universitat de València, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Institut Català d'Oncologia Badalona-HU Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; Hospital de Mataró (Consorci Sanitari del Maresme), Mataró, Barcelona, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital General de Granollers, Granollers, Barcelona, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain
| | - M Velasco
- Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Hospital Universitario de Salamanca-IBSAL, Zaragoza, Spain; Hospital Universitario Virgen de las Nieves, Granada, Spain; Hospital Clínico de Valencia, Instituto de Investigación Sanitaria INCLIVA, Universitat de València, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Institut Català d'Oncologia Badalona-HU Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; Hospital de Mataró (Consorci Sanitari del Maresme), Mataró, Barcelona, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital General de Granollers, Granollers, Barcelona, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain
| | - L Gonzalez-Cortijo
- Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Hospital Universitario de Salamanca-IBSAL, Zaragoza, Spain; Hospital Universitario Virgen de las Nieves, Granada, Spain; Hospital Clínico de Valencia, Instituto de Investigación Sanitaria INCLIVA, Universitat de València, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Institut Català d'Oncologia Badalona-HU Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; Hospital de Mataró (Consorci Sanitari del Maresme), Mataró, Barcelona, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital General de Granollers, Granollers, Barcelona, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain
| | - L Jolis
- Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Hospital Universitario de Salamanca-IBSAL, Zaragoza, Spain; Hospital Universitario Virgen de las Nieves, Granada, Spain; Hospital Clínico de Valencia, Instituto de Investigación Sanitaria INCLIVA, Universitat de València, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Institut Català d'Oncologia Badalona-HU Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; Hospital de Mataró (Consorci Sanitari del Maresme), Mataró, Barcelona, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital General de Granollers, Granollers, Barcelona, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain
| | - T Pascual
- Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Hospital Universitario de Salamanca-IBSAL, Zaragoza, Spain; Hospital Universitario Virgen de las Nieves, Granada, Spain; Hospital Clínico de Valencia, Instituto de Investigación Sanitaria INCLIVA, Universitat de València, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Institut Català d'Oncologia Badalona-HU Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; Hospital de Mataró (Consorci Sanitari del Maresme), Mataró, Barcelona, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital General de Granollers, Granollers, Barcelona, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain
| | - Y Amigo
- Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Hospital Universitario de Salamanca-IBSAL, Zaragoza, Spain; Hospital Universitario Virgen de las Nieves, Granada, Spain; Hospital Clínico de Valencia, Instituto de Investigación Sanitaria INCLIVA, Universitat de València, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Institut Català d'Oncologia Badalona-HU Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; Hospital de Mataró (Consorci Sanitari del Maresme), Mataró, Barcelona, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital General de Granollers, Granollers, Barcelona, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain
| | - M Casas
- Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Hospital Universitario de Salamanca-IBSAL, Zaragoza, Spain; Hospital Universitario Virgen de las Nieves, Granada, Spain; Hospital Clínico de Valencia, Instituto de Investigación Sanitaria INCLIVA, Universitat de València, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Institut Català d'Oncologia Badalona-HU Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; Hospital de Mataró (Consorci Sanitari del Maresme), Mataró, Barcelona, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital General de Granollers, Granollers, Barcelona, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain
| | - MC Cámara
- Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Hospital Universitario de Salamanca-IBSAL, Zaragoza, Spain; Hospital Universitario Virgen de las Nieves, Granada, Spain; Hospital Clínico de Valencia, Instituto de Investigación Sanitaria INCLIVA, Universitat de València, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Institut Català d'Oncologia Badalona-HU Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; Hospital de Mataró (Consorci Sanitari del Maresme), Mataró, Barcelona, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital General de Granollers, Granollers, Barcelona, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain
| | - E Carrasco
- Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Hospital Universitario de Salamanca-IBSAL, Zaragoza, Spain; Hospital Universitario Virgen de las Nieves, Granada, Spain; Hospital Clínico de Valencia, Instituto de Investigación Sanitaria INCLIVA, Universitat de València, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Institut Català d'Oncologia Badalona-HU Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; Hospital de Mataró (Consorci Sanitari del Maresme), Mataró, Barcelona, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital General de Granollers, Granollers, Barcelona, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain
| | - A Casas
- Hospital Universitario 12 de Octubre, Madrid, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Hospital Universitario de Salamanca-IBSAL, Zaragoza, Spain; Hospital Universitario Virgen de las Nieves, Granada, Spain; Hospital Clínico de Valencia, Instituto de Investigación Sanitaria INCLIVA, Universitat de València, Valencia, Spain; Hospital del Mar, Barcelona, Spain; Institut Català d'Oncologia Badalona-HU Germans Trias i Pujol, Badalona, Barcelona, Spain; Hospital Universitario Miguel Servet, Zaragoza, Spain; Hospital Universitario de Fuenlabrada, Madrid, Spain; Hospital Virgen de la Salud, Toledo, Spain; Hospital de Mataró (Consorci Sanitari del Maresme), Mataró, Barcelona, Spain; Hospital Universitario Quirón de Madrid, Madrid, Spain; Hospital General de Granollers, Granollers, Barcelona, Spain; GEICAM, Spanish Breast Cancer Group, Madrid, Spain
| |
Collapse
|
14
|
López-Froilán R, Ramírez-Moreno E, Podio NS, Pérez-Rodríguez ML, Cámara M, Baroni MV, Wunderlin DA, Sánchez-Mata MC. In vitro assessment of potential intestinal absorption of some phenolic families and carboxylic acids from commercial instant coffee samples. Food Funct 2016; 7:2706-11. [DOI: 10.1039/c6fo00315j] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Coffee is a source of flavors and bioactive compounds with wide differences in their bioaccesibility.
Collapse
Affiliation(s)
- R. López-Froilán
- Universidad Complutense de Madrid
- Facultad de Farmacia
- Departamento de Nutrición y Bromatología II
- Bromatología
- Madrid
| | - E. Ramírez-Moreno
- Centro de Investigación Interdisciplinario. Área Académica de Nutrición
- Instituto de Ciencias de la Salud
- Universidad Autónoma del Estado de Hidalgo
- Pachuca
- México
| | - N. S. Podio
- Universidad Nacional de Córdoba-CONICET; ISIDSA-ICYTAC
- Córdoba
- Argentina
| | - M. L. Pérez-Rodríguez
- Universidad Complutense de Madrid
- Facultad de Farmacia
- Departamento de Nutrición y Bromatología II
- Bromatología
- Madrid
| | - M. Cámara
- Universidad Complutense de Madrid
- Facultad de Farmacia
- Departamento de Nutrición y Bromatología II
- Bromatología
- Madrid
| | - M. V. Baroni
- Universidad Nacional de Córdoba-CONICET; ISIDSA-ICYTAC
- Córdoba
- Argentina
| | - D. A. Wunderlin
- Universidad Nacional de Córdoba-CONICET; ISIDSA-ICYTAC
- Córdoba
- Argentina
| | - M. C. Sánchez-Mata
- Universidad Complutense de Madrid
- Facultad de Farmacia
- Departamento de Nutrición y Bromatología II
- Bromatología
- Madrid
| |
Collapse
|
15
|
Rahman T, Alshahrani M, Irie Y, Cámara M, Martínez-Pomares L. WS10.7 The role of C-type lectins in the recognition of Pseudomonas aeruginosa. J Cyst Fibros 2015. [DOI: 10.1016/s1569-1993(15)30068-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
16
|
Muntaka S, Asante A, Cámara M, Martínez-Pomares L. 34 Phagocyte collaboration for the control of Pseudomonas aeruginosa. J Cyst Fibros 2015. [DOI: 10.1016/s1569-1993(15)30211-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
17
|
|
18
|
García-Herrera P, Morales P, Fernández-Ruiz V, Sánchez-Mata M, Cámara M, Carvalho A, Ferreira I, Pardo-de-Santayana M, Molina M, Tardio J. Nutrients, phytochemicals and antioxidant activity in wild populations of Allium ampeloprasum L., a valuable underutilized vegetable. Food Res Int 2014. [DOI: 10.1016/j.foodres.2014.03.004] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
19
|
Carañana V, Ramos M, Damau E, García-Saenz JA, González X, Murillo L, Calvo L, Morales S, González-Farré A, Fernández-Morales LA, Carrasco E, Casas MI, Angulo M, Cámara MC, García AI, Llombart A, Jara C. Abstract P3-15-02: A prospective, open label, non-comparative trial to determine the incidence of chemotherapy-induced nausea and vomiting associated with the docetaxel-cyclophosphamide regimen in early breast cancer patients. Results from the GEICAM 2009-02 study. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p3-15-02] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Docetaxel-Cyclophosphamide (TC) has become a common chemotherapy regimen for moderate-high risk Early Breast Cancer (EBC) patients. The incidence of chemotherapy induced nausea and vomiting (CINV) with TC together with an adequate standard anti-emetic therapy with 5-HT3 antagonist and corticosteroids are unknown. This study investigates the incidence of emesis control (complete response), defined as no vomiting (any grade of NCI CTCAE version 4.0) and no use of rescue treatment within 120 hours after the first cycle of TC. Secondary objective evaluates the efficacy of Aprepitant in non-responding patients.
Methods: EBC patients with no prior moderate-high risk CINV were included. Patients received Docetaxel 75 mg/m2 plus Cyclophosphamide 600 mg/m2 IV every three weeks. Antiemetic treatment consisted of oral Dexamethasone (D) 8 mg (at night) on day 0; oral D 8 mg x 3 (in the morning, 1 hour before chemotherapy and at night) plus 5-HT3 antagonists on day 1; and oral D 8 mg x 2 (in the morning and at night) on days 2 and 3. Non-responding patients (vomiting or need of rescue therapy in the first cycle) were offered participation in the efficacy phase (Aprepitant 125mg day 1 and 80 mg days 2 and 3 added to the standard antiemetic therapy in cycle 2). In addition to the standard NCI-CTCAE adverse event collection, a patient´s diary (from day 1 to 6) and the FLIE (Functional Living Index-Emesis questionnaire) were used. Assuming a 25% (+/- 6%) of patients resistant to standard antiemetic therapy, 212 patients were estimated.
Results: From May-11 to March-13, 212 EBC patients were included. Median age was 57 years (range 34-82), 29.3% were premenopausal. Twenty-seven patients were excluded from the main analysis because of major protocol violations (25) or consent withdrawal (2). Twenty-four patients (13%; IC95%: 8.2 – 17.8) did not respond to standard antiemetics and entered the efficacy phase with Aprepitant. From these 24 patients, 14 (56%; IC95%: 36.5 – 75.5) achieved a complete response on cycle 2. No adverse events related to Aprepitant were observed.
Conclusions: Proper use of standard antiemetic therapy for early breast cancer patients treated with TC provides a high control rate (87%). Among no responding patients, about half of them were rescued with Aprepitant. Identification of the non-responding patients could lead to a better antiemetic control with Aprepitant from the first cycle.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P3-15-02.
Collapse
Affiliation(s)
- V Carañana
- Hospital Arnau de Vilanova, Valencia, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Corporació Sanitaria Par Tauli, Sabadell, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Clinic i Provincial, Barcelona, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Arnau de Vilanova, Lleida, Spain; GEICAM (Spanish Breast Cancer Research Group), Madrid, Spain; Fundación Hospital Alrcorcón, Alcorcón, Madrid
| | - M Ramos
- Hospital Arnau de Vilanova, Valencia, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Corporació Sanitaria Par Tauli, Sabadell, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Clinic i Provincial, Barcelona, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Arnau de Vilanova, Lleida, Spain; GEICAM (Spanish Breast Cancer Research Group), Madrid, Spain; Fundación Hospital Alrcorcón, Alcorcón, Madrid
| | - E Damau
- Hospital Arnau de Vilanova, Valencia, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Corporació Sanitaria Par Tauli, Sabadell, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Clinic i Provincial, Barcelona, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Arnau de Vilanova, Lleida, Spain; GEICAM (Spanish Breast Cancer Research Group), Madrid, Spain; Fundación Hospital Alrcorcón, Alcorcón, Madrid
| | - JA García-Saenz
- Hospital Arnau de Vilanova, Valencia, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Corporació Sanitaria Par Tauli, Sabadell, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Clinic i Provincial, Barcelona, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Arnau de Vilanova, Lleida, Spain; GEICAM (Spanish Breast Cancer Research Group), Madrid, Spain; Fundación Hospital Alrcorcón, Alcorcón, Madrid
| | - X González
- Hospital Arnau de Vilanova, Valencia, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Corporació Sanitaria Par Tauli, Sabadell, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Clinic i Provincial, Barcelona, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Arnau de Vilanova, Lleida, Spain; GEICAM (Spanish Breast Cancer Research Group), Madrid, Spain; Fundación Hospital Alrcorcón, Alcorcón, Madrid
| | - L Murillo
- Hospital Arnau de Vilanova, Valencia, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Corporació Sanitaria Par Tauli, Sabadell, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Clinic i Provincial, Barcelona, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Arnau de Vilanova, Lleida, Spain; GEICAM (Spanish Breast Cancer Research Group), Madrid, Spain; Fundación Hospital Alrcorcón, Alcorcón, Madrid
| | - L Calvo
- Hospital Arnau de Vilanova, Valencia, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Corporació Sanitaria Par Tauli, Sabadell, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Clinic i Provincial, Barcelona, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Arnau de Vilanova, Lleida, Spain; GEICAM (Spanish Breast Cancer Research Group), Madrid, Spain; Fundación Hospital Alrcorcón, Alcorcón, Madrid
| | - S Morales
- Hospital Arnau de Vilanova, Valencia, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Corporació Sanitaria Par Tauli, Sabadell, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Clinic i Provincial, Barcelona, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Arnau de Vilanova, Lleida, Spain; GEICAM (Spanish Breast Cancer Research Group), Madrid, Spain; Fundación Hospital Alrcorcón, Alcorcón, Madrid
| | - A González-Farré
- Hospital Arnau de Vilanova, Valencia, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Corporació Sanitaria Par Tauli, Sabadell, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Clinic i Provincial, Barcelona, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Arnau de Vilanova, Lleida, Spain; GEICAM (Spanish Breast Cancer Research Group), Madrid, Spain; Fundación Hospital Alrcorcón, Alcorcón, Madrid
| | - LA Fernández-Morales
- Hospital Arnau de Vilanova, Valencia, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Corporació Sanitaria Par Tauli, Sabadell, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Clinic i Provincial, Barcelona, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Arnau de Vilanova, Lleida, Spain; GEICAM (Spanish Breast Cancer Research Group), Madrid, Spain; Fundación Hospital Alrcorcón, Alcorcón, Madrid
| | - E Carrasco
- Hospital Arnau de Vilanova, Valencia, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Corporació Sanitaria Par Tauli, Sabadell, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Clinic i Provincial, Barcelona, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Arnau de Vilanova, Lleida, Spain; GEICAM (Spanish Breast Cancer Research Group), Madrid, Spain; Fundación Hospital Alrcorcón, Alcorcón, Madrid
| | - MI Casas
- Hospital Arnau de Vilanova, Valencia, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Corporació Sanitaria Par Tauli, Sabadell, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Clinic i Provincial, Barcelona, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Arnau de Vilanova, Lleida, Spain; GEICAM (Spanish Breast Cancer Research Group), Madrid, Spain; Fundación Hospital Alrcorcón, Alcorcón, Madrid
| | - MdM Angulo
- Hospital Arnau de Vilanova, Valencia, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Corporació Sanitaria Par Tauli, Sabadell, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Clinic i Provincial, Barcelona, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Arnau de Vilanova, Lleida, Spain; GEICAM (Spanish Breast Cancer Research Group), Madrid, Spain; Fundación Hospital Alrcorcón, Alcorcón, Madrid
| | - MC Cámara
- Hospital Arnau de Vilanova, Valencia, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Corporació Sanitaria Par Tauli, Sabadell, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Clinic i Provincial, Barcelona, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Arnau de Vilanova, Lleida, Spain; GEICAM (Spanish Breast Cancer Research Group), Madrid, Spain; Fundación Hospital Alrcorcón, Alcorcón, Madrid
| | - AI García
- Hospital Arnau de Vilanova, Valencia, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Corporació Sanitaria Par Tauli, Sabadell, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Clinic i Provincial, Barcelona, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Arnau de Vilanova, Lleida, Spain; GEICAM (Spanish Breast Cancer Research Group), Madrid, Spain; Fundación Hospital Alrcorcón, Alcorcón, Madrid
| | - A Llombart
- Hospital Arnau de Vilanova, Valencia, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Corporació Sanitaria Par Tauli, Sabadell, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Clinic i Provincial, Barcelona, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Arnau de Vilanova, Lleida, Spain; GEICAM (Spanish Breast Cancer Research Group), Madrid, Spain; Fundación Hospital Alrcorcón, Alcorcón, Madrid
| | - C Jara
- Hospital Arnau de Vilanova, Valencia, Spain; Centro Oncológico de Galicia, A Coruña, Spain; Corporació Sanitaria Par Tauli, Sabadell, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital Clinic i Provincial, Barcelona, Spain; Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Complejo Hospitalario Universitario A Coruña, A Coruña, Spain; Hospital Arnau de Vilanova, Lleida, Spain; GEICAM (Spanish Breast Cancer Research Group), Madrid, Spain; Fundación Hospital Alrcorcón, Alcorcón, Madrid
| |
Collapse
|
20
|
Cámara M, Gallego-Picó A, Garcinuño R, Fernández-Hernando P, Durand-Alegría J, Sánchez P. An HPLC-DAD method for the simultaneous determination of nine β-lactam antibiotics in ewe milk. Food Chem 2013; 141:829-34. [DOI: 10.1016/j.foodchem.2013.02.131] [Citation(s) in RCA: 57] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2011] [Revised: 10/24/2012] [Accepted: 02/22/2013] [Indexed: 02/06/2023]
|
21
|
Abstract
Polyunsaturated fatty acids play an important role in human nutrition, being associated with several health benefits. The analyzed vegetables, in spite of its low fat content, lower than 2%, present a high proportion of polyunsaturated fatty acids of n-3, n-6 and n-9 series, such as α-linolenic, linoleic and oleic acids, respectively. Wild edible plants contain in general a good balance of n-6 and n-3 fatty acids. The present study tries to contribute to the preservation and valorization of traditional food resources, studying the fatty acids profile of 20 wild vegetables by gas-liquid chromatography with flame ionization detection. Results show that species in which leaves are predominant in their edible parts have in general the highest polyunsaturated fatty acid/saturated fatty acid ratios: Rumex pulcher (5.44), Cichorium intybus (5.14) and Papaver rhoeas (5.00). Due to the low n-6/n-3 ratios of the majority of the samples, they can be considered interesting sources of n-3 fatty acids, especially those with higher total fat amount, such as Bryonia dioica, Chondrilla juncea or Montia fontana, with the highest contents of α-linolenic acid (67.78, 56.27 and 47.65%, respectively). The wild asparaguses of Asparagus acutifolius and Tamus communis stand out for their linoleic acid content (42.29 and 42.45%, respectively). All these features reinforce the interest of including wild plants in diet, as an alternative to the variety of vegetables normally used.
Collapse
Affiliation(s)
- P Morales
- Instituto Politécnico de Bragança, Campus de Santa Apolónia, Apartado, Bragança, Portugal
| | | | | | | | | | | |
Collapse
|
22
|
San José Rodriguez R, Fernández-Ruiz V, Cámara M, Sánchez-Mata M. Simultaneous determination of vitamin B1 and B2 in complex cereal foods, by reverse phase isocratic HPLC-UV. J Cereal Sci 2012. [DOI: 10.1016/j.jcs.2011.12.011] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
23
|
|
24
|
Liu X, Jia J, Atkinson S, Cámara M, Gao K, Li H, Cao J. Biocontrol potential of an endophytic Serratia sp. G3 and its mode of action. World J Microbiol Biotechnol 2010. [DOI: 10.1007/s11274-010-0321-y] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
25
|
Yu R, Zhang X, Ruiz G, Tarifa M, Cámara M. Evolution of the fracture process zone in high-strength concrete under different loading rates. EPJ Web of Conferences 2010. [DOI: 10.1051/epjconf/20100623006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
26
|
Diaz A, Junquera ML, Esteban V, Martínez B, Pueyo I, Suarez J, Ureña JM, Varela JA, Vall M, del Romero J, Sanz I, Belda J, Boronat J, Gomez P, Gual F, Colomo C, López de Munain J, Balaguer J, Landa MC, Lezaun ME, Cámara MC, Fernández E, Bru FJ, Alastrue I, Ordoñana JR, de Armas C, Azpiri MA, Gomez L, Trullén J, Diez M. HIV/STI co-infection among men who have sex with men in Spain. ACTA ACUST UNITED AC 2009; 14. [PMID: 20003899 DOI: 10.2807/ese.14.48.19426-en] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
In Spain, neither the HIV nor the STI national surveillance systems collect information on HIV/STI co-infection. However, there are two networks based on HIV/STI clinics which gather this data. We describe HIV prevalence in men who have sex with men (MSM) diagnosed with infectious syphilis and/or gonorrhoea in 15 STI clinics; and concurrent diagnoses of STI in MSM newly diagnosed with HIV in 19 HIV/STI clinics. In total, 572 MSM were diagnosed with infectious syphilis and 580 with gonorrhoea during 2005-2007. HIV prevalence among syphilis and gonorrhoea cases was 29.8% and 15.2% respectively. In the multivariate analysis, HIV/syphilis co-infection was associated with being Latin American; having a history of STI; reporting exclusively anal intercourse; and having sex with casual or several types of partners. HIV and gonorrhoea co-infection was associated with age older than 45 years; having no education or only primary education completed; and having a history of STI. In total, 1,462 HIV infections were newly diagnosed among MSM during 2003-2007. Of these, 31.0% were diagnosed with other STI at the same time. Factors associated with STI co-infection among new HIV cases in MSM were being Latin American; and having sex with casual partners or with both steady and casual partners. In Spain, a considerable proportion of MSM are co-infected with HIV and STI.
Collapse
Affiliation(s)
- A Diaz
- Area de Epidemiologia del VIH, Centro Nacional de Epidemiologia, Instituto de Salud Carlos III, Madrid, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Cámara M, Cebadera E. Antigens production in plants as edible vaccines: a great promise. N Biotechnol 2009. [DOI: 10.1016/j.nbt.2009.06.655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
28
|
Alcalde E, Cámara M. General surveillance of GMOs, open questions. N Biotechnol 2009. [DOI: 10.1016/j.nbt.2009.06.544] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
29
|
|
30
|
Cámara M, Matallana M, Sánchez - Mata M, Lillo Ayué R, Labra E. LYCOPENE AND HYDROXYMETHYLFURFURAL (HMF) EVALUATION IN TOMATO PRODUCTS. ACTA ACUST UNITED AC 2003. [DOI: 10.17660/actahortic.2003.613.59] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
31
|
Ward C, Cámara M, Forrest I, Rutherford R, Pritchard G, Daykin M, Hardman A, de Soyza A, Fisher AJ, Williams P, Corris PA. Preliminary findings of quorum signal molecules in clinically stable lung allograft recipients. Thorax 2003; 58:444-6. [PMID: 12728169 PMCID: PMC1746678 DOI: 10.1136/thorax.58.5.444] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND Infection with bacteria such as Pseudomonas is common in lung allograft recipients, particularly during chronic rejection. Analysis of sputum samples from patients with cystic fibrosis infected with Pseudomonas aeruginosa or Burkholderia cepacia has indicated the presence of bacterial N-acylhomoserine lactones (AHLs) quorum sensing signalling molecules. AHLs not only control the expression of bacterial virulence genes but are also involved in stimulating the maturation of antibiotic resistant biofilms and host chemokine release. It was hypothesised that AHLs may be detected even in clinically stable lung transplant recipients free of clinical infection or rejection. METHODS Three 60 ml samples of bronchoalveolar lavage (BAL) fluid were taken from nine stable lung transplant recipients 3-12 months after transplantation. Detection of AHLs was carried out on dichloromethane extracted supernatants using the bioluminescence based AHL reporter plasmid pSB1075. This responds to the presence of AHLs with long acyl chains (C10-C14), generating light. Synthetic AHLs were included as positive controls. RESULTS Five of the nine BAL fluid supernatants exhibited AHL activity, suggesting the presence of AHLs with long N-acyl chains. There was no correlation between the levels of AHLs detected or their absence and BAL fluid microbiology or diagnosis before transplantation. CONCLUSIONS This is the first evidence for the presence of AHL quorum sensing signals in human lung allograft recipients, even in subjects with no rejection or apparent infection. Further longitudinal follow up of these preliminary findings is required to elucidate potential links with infection, rejection, and allograft deterioration.
Collapse
Affiliation(s)
- C Ward
- ImmunoBiology and Transplantation Group, University of Newcastle upon Tyne and The Freeman Hospital, Newcastle upon Tyne NE7 7DN, UK.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Pessi G, Williams F, Hindle Z, Heurlier K, Holden MT, Cámara M, Haas D, Williams P. The global posttranscriptional regulator RsmA modulates production of virulence determinants and N-acylhomoserine lactones in Pseudomonas aeruginosa. J Bacteriol 2001; 183:6676-83. [PMID: 11673439 PMCID: PMC95500 DOI: 10.1128/jb.183.22.6676-6683.2001] [Citation(s) in RCA: 262] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Posttranscriptional control is known to contribute to the regulation of secondary metabolism and virulence determinants in certain gram-negative bacteria. Here we report the isolation of a Pseudomonas aeruginosa gene which encodes a global translational regulatory protein, RsmA (regulator of secondary metabolites). Overexpression of rsmA resulted in a substantial reduction in the levels of extracellular products, including protease, elastase, and staphylolytic (LasA protease) activity as well as the PA-IL lectin, hydrogen cyanide (HCN), and the phenazine pigment pyocyanin. While inactivation of rsmA in P. aeruginosa had only minor effects on the extracellular enzymes and the PA-IL lectin, the production of HCN and pyocyanin was enhanced during the exponential phase. The influence of RsmA on N-acylhomoserine lactone-mediated quorum sensing was determined by assaying the levels of N-(3-oxododecanoyl)homoserine lactone (3-oxo-C12-HSL) and N-butanoylhomoserine lactone (C4-HSL) produced by the rsmA mutant and the rsmA-overexpressing strain. RsmA exerted a negative effect on the synthesis of both 3-oxo-C12-HSL and C4-HSL, which was confirmed by using lasI and rhlI translational fusions. These data also highlighted the temporal expression control of the lasI gene, which was induced much earlier and to a higher level during the exponential growth phase in an rsmA mutant. To investigate whether RsmA modulates HCN production solely via quorum-sensing control, hcn translational fusions were employed to monitor the regulation of the cyanide biosynthesis genes (hcnABC). RsmA was shown to exert an additional negative effect on cyanogenesis posttranscriptionally by acting on a region surrounding the hcnA ribosome-binding site. This suggests that, in P. aeruginosa, RsmA functions as a pleiotropic posttranscriptional regulator of secondary metabolites directly and also indirectly by modulating the quorum-sensing circuitry.
Collapse
Affiliation(s)
- G Pessi
- Laboratoire de Biologie Microbienne, Université de Lausanne, CH-1015 Lausanne, Switzerland
| | | | | | | | | | | | | | | |
Collapse
|
33
|
|
34
|
Dexter SJ, Pearson RG, Davies MC, Cámara M, Shakesheff KM. A comparison of the adhesion of mammalian cells and Staphylococcus epidermidis on fibronectin-modified polymer surfaces. J Biomed Mater Res 2001; 56:222-7. [PMID: 11340592 DOI: 10.1002/1097-4636(200108)56:2<222::aid-jbm1087>3.0.co;2-l] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
The modification of polymer surfaces to mimic the extracellular matrix, and therefore, stimulate cell growth via receptor-mediated interactions, is one approach used to promote the integration of tissue-engineering scaffolds and biomaterials into the body. However, by optimizing surfaces for tissue integration it is likely that bacterial adhesion may also be affected, resulting in a greater risk of biomaterial-related infection. This could be detrimental to both the implant and the patient because biomaterial related infections are particularly resistant to host defenses and antibiotics. In this study, we analyzed the adhesion of a Staphylococcus epidermidis clinical isolate and 3T3 rat fibroblasts to tissue culture plastic coated with varying concentrations of fibronectin (Fn). Bacterial adhesion was always lower than tissue culture plastic and appeared to decrease with increasing Fn concentrations. Mammalian cell adhesion to Fn exceeded adhesion to tissue culture plastic but did not differ significantly over the range of protein concentrations or between 1 and 4 h of incubation. In most cases, the total surface coverage did not vary with time or Fn concentration, indicating that maximal cell adhesion and spreading occurred rapidly and at low protein concentrations. This study suggests that, by controlling the density of proteins or ligands on a surface, we can potentially optimize mammalian cell adhesion without stimulating bacterial adhesion, hence reducing the likelihood of infection.
Collapse
Affiliation(s)
- S J Dexter
- School of Pharmaceutical Sciences, University of Nottingham, University Park, Nottingham, England, NG7 2RD
| | | | | | | | | |
Collapse
|
35
|
Milton DL, Chalker VJ, Kirke D, Hardman A, Cámara M, Williams P. The LuxM homologue VanM from Vibrio anguillarum directs the synthesis of N-(3-hydroxyhexanoyl)homoserine lactone and N-hexanoylhomoserine lactone. J Bacteriol 2001; 183:3537-47. [PMID: 11371516 PMCID: PMC95229 DOI: 10.1128/jb.183.12.3537-3547.2001] [Citation(s) in RCA: 99] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Vibrio anguillarum, which causes terminal hemorrhagic septicemia in fish, was previously shown to possess a LuxRI-type quorum-sensing system (vanRI) and to produce N-(3-oxodecanoyl)homoserine lactone (3-oxo-C10-HSL). However, a vanI null mutant still activated N-acylhomoserine lactone (AHL) biosensors, indicating the presence of an additional quorum-sensing circuit in V. anguillarum. In this study, we have characterized this second system. Using high-pressure liquid chromatography in conjunction with mass spectrometry and chemical analysis, we identified two additional AHLs as N-hexanoylhomoserine lactone (C6-HSL) and N-(3-hydroxyhexanoyl)homoserine lactone (3-hydroxy-C6-HSL). Quantification of each AHL present in stationary-phase V. anguillarum spent culture supernatants indicated that 3-oxo-C10-HSL, 3-hydroxy-C6-HSL, and C6-HSL are present at approximately 8.5, 9.5, and 0.3 nM, respectively. Furthermore, vanM, the gene responsible for the synthesis of these AHLs, was characterized and shown to be homologous to the luxL and luxM genes, which are required for the production of N-(3-hydroxybutanoyl)homoserine lactone in Vibrio harveyi. However, resequencing of the V. harveyi luxL/luxM junction revealed a sequencing error present in the published sequence, which when corrected resulted in a single open reading frame (termed luxM). Downstream of vanM, we identified a homologue of luxN (vanN) that encodes a hybrid sensor kinase which forms part of a phosphorelay cascade involved in the regulation of bioluminescence in V. harveyi. A mutation in vanM abolished the production of C6-HSL and 3-hydroxy-C6-HSL. In addition, production of 3-oxo-C10-HSL was abolished in the vanM mutant, suggesting that 3-hydroxy-C6-HSL and C6-HSL regulate the production of 3-oxo-C10-HSL via vanRI. However, a vanN mutant displayed a wild-type AHL profile. Neither mutation affected either the production of proteases or virulence in a fish infection model. These data indicate that V. anguillarum possesses a hierarchical quorum sensing system consisting of regulatory elements homologous to those found in both V. fischeri (the LuxRI homologues VanRI) and V. harveyi (the LuxMN homologues, VanMN).
Collapse
Affiliation(s)
- D L Milton
- Department of Cell and Molecular Biology, Umeå University, S-901 87 Umeå, Sweden.
| | | | | | | | | | | |
Collapse
|
36
|
Abstract
Primary appendicular adenocarcinoma is rare. We report an unusual mucinous appendicular adenocarcinoma during pregnancy. To our knowledge, this is the second reported case in the literature. A mucinous appendicular cystoadenocarcinoma was discovered unexpectedly and coincidentally during a cesarean section performed in term pregnancy. An appendectomy was simultaneously performed, followed by a right hemicolectomy. Given the exceptionally low incidence tumors co-existing with pregnancy, we recommend a careful and complete appendix examination during cesarean and postpartum sterilization, and subsequent removal of tumors should they exist.
Collapse
Affiliation(s)
- J L Gallo
- Department of Obstetrics and Gynecology, Montril General Hospital, Granada, Spain
| | | | | | | |
Collapse
|
37
|
Sánchez T, Soriano MJ, Almarza JL, Cámara M, Paricio P. [Diagnosis of cerebral toxoplasmosis in an immunocompetent patient]. Enferm Infecc Microbiol Clin 2000; 18:46-8. [PMID: 10721565] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
|
38
|
Delás MA, Artero JM, Andrés Martínez J, Cámara M, Segovia M. [Pulmonary cystic image and anaphylaxis]. Enferm Infecc Microbiol Clin 1997; 15:557-9. [PMID: 9522522] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Affiliation(s)
- M A Delás
- Servicio de Microbiología, Hospital General Universitario de Murcia
| | | | | | | | | |
Collapse
|
39
|
Toldos CM, Ortiz G, Cámara M, Segovia M. Application of pulsed-field gel electrophoresis in an outbreak of infection due to Klebsiella oxytoca. J Med Microbiol 1997; 46:889-90. [PMID: 9364148] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
|
40
|
Pons-Lladó G, Carreras F, Borrás X, Ramírez I, Cámara M, Padró JM, Caralps JM, Arís A. Doppler-derived gradients in normally functioning Monostrut Björk-Shiley prostheses. Am J Cardiol 1995; 76:100-3. [PMID: 7793394 DOI: 10.1016/s0002-9149(99)80815-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
In summary, reference values of Doppler gradients obtained in a large number of patients with normal-functioning mitral and aortic Monostrut Björk-Shiley prostheses are reported. It is shown that the value of the transprosthetic gradient increases with decreasing valve size in patients with aortic prostheses. No individual significant variations of the transprothetic Doppler gradient during a 3-year follow-up were observed.
Collapse
Affiliation(s)
- G Pons-Lladó
- Department de Cardiologia i Cirurgia Cardiaca, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Cámara M, Meseguer MD, Artero JM, Segovia M. [Visceral leishmaniasis and AIDS: detection of Leishmania infantum antibodies with western blot]. Enferm Infecc Microbiol Clin 1995; 13:268-9. [PMID: 7779890] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
|
42
|
Abstract
A gene from Streptococcus pneumoniae (nanA), with features entirely consistent with a neuraminidase gene, has been sequenced. High levels of neuraminidase activity were obtained after cloning of this gene, without flanking sequences, into a high-expression vector. RNA hybridization studies have shown that the gene is transcribed by a virulent pneumococcus strain. The predicted molecular weight of the protein and certain amino acid sequences are typical of other neuraminidases. NanA contains the four copies of the sequence SXDXGXTW that is present in all the bacterial neuraminidases previously described. Kyte and Doolittle analysis showed that NanA is a hydrophilic protein with hydrophobic domains at the N terminus and the C terminus. A putative signal peptide was found in the N terminus of this protein, indicating that the protein is exported from the pneumococcus. The C terminus has the features of the anchor motif found in other surface proteins from gram-positive bacteria. Electron microscopy studies showed the presence of neuraminidase associated with the cell surface of the pneumococcus.
Collapse
Affiliation(s)
- M Cámara
- Department of Microbiology and Immunology, University of Leicester, United Kingdom
| | | | | | | |
Collapse
|
43
|
Tortosa CG, Vargas ML, Cámara M, Alemán P, Montes MJ, Ruiz C, Olivares EG. Expression of adhesion molecules by endothelial cells of early human decidua. Virchows Arch A Pathol Anat Histopathol 1993; 423:287-90. [PMID: 7694423 DOI: 10.1007/bf01606892] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
The expression of adhesion molecules by endothelial cells (EC) of early human decidua was studied with monoclonal antibodies and the immunoperoxidase technique. Although E-selectin, INCAM-110 and VCAM-1 were poorly detected on decidual EC, ICAM-1, P-selectin and DR antigens were highly expressed by these cells, some of which showed high endothelial venule-like morphology. Our results suggest that decidual EC are activated, and are probably involved in the active recruitment of leucocytes.
Collapse
Affiliation(s)
- C G Tortosa
- Departamento de Bioquímica y Biología Molecular, Facultad de Medicina, Universidad de Granada, Spain
| | | | | | | | | | | | | |
Collapse
|
44
|
García-Tortosa C, Vargas ML, Cámara M, Alemán P, Montes MJ, Ruiz C, García-Olivares E. Expression of class II HLA molecules by endothelial cells of human decidua. Life Sci 1993; 52:1947-54. [PMID: 8505860 DOI: 10.1016/0024-3205(93)90635-g] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Many authors have documented a high level of expression of class II HLA molecules by decidua. Although macrophages appear to be responsible for this, we show in this article that endothelial cells (EC) of the venules and capillaries of human decidua also strongly express class II molecules, whereas EC of chorionic villi do not. We discuss this finding in the context of the maternal-fetal immune interaction.
Collapse
Affiliation(s)
- C García-Tortosa
- Departamento de Bioquímica, Facultad de Medicina, Universidad de Granada, Spain
| | | | | | | | | | | | | |
Collapse
|
45
|
Salamanca A, Gonzalez-Gomez F, Padilla MC, Sabatel RM, Cámara M, Cuadros JL. Prenatal ultrasound semiography of anencephaly: sonographic-pathological correlations. Ultrasound Obstet Gynecol 1992; 2:95-100. [PMID: 12796984 DOI: 10.1046/j.1469-0705.1992.02020095.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
Abstract
A better understanding of the ultrasound findings in each of the different types of fetal anencephaly can help to reduce the number of false-negative diagnoses of this condition during the prenatal period. Errors in the estimation of the remaining cerebral tissue (angiomatous stroma, area cerebrovasculosa) can cause false-negative diagnoses or diagnostic confusion with cases of microcephaly or incomplete ossification of the cranial vault. In a retrospective study, 30 fetuses with anencephaly (diagnosed at 13-38 weeks of gestation) were grouped, in terms of their ultrasound results, according to the Nanagas classification. The ultrasound diagnoses were then correlated with those found through autopsy, to identify any errors in the ultrasound classification.
Collapse
Affiliation(s)
- A Salamanca
- Department of Obstetrics and Gynecology, University of Granada Medical School, Granada, Spain
| | | | | | | | | | | |
Collapse
|
46
|
Zarzuelo A, Risco S, Gámez MJ, Jimenez J, Cámara M, Martinez MA. Hypoglycemic action of Salvia lavandulifolia Vahl. spp. oxyodon:a contribution to studies on the mechanism of action. Life Sci 1990; 47:909-15. [PMID: 2215073 DOI: 10.1016/0024-3205(90)90537-2] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Having previously demonstrated the hypoglycemic action of Salvia lavandulifolia Vahl, subspecies oxyodon, the mechanism of action was further investigated. The hypoglycemic action may be the result of several synchronous mechanisms: a) potentiation of insulin release induced by glucose, b) increased peripheral uptake of glucose, c) decreased intestinal absorption of glucose and d) hyperplasia of the pancreatic islet beta cells (seen after chronic treatment).
Collapse
Affiliation(s)
- A Zarzuelo
- Departamento de Farmacología, Facultad de Farmacia, Universidad de Granada, Spain
| | | | | | | | | | | |
Collapse
|
47
|
Arráez MA, Aguilar D, O'Valle F, Cámara M, Fernández P, García del Moral R. [Malignant astrocytic glioma of the brain in adults: histologic criteria determining its classification, diagnosis and prognosis]. Neurologia 1989; 4:311-5. [PMID: 2638595] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
Eighty-three malignant supratenorial astrocytic gliomas in adult patients were evaluated. The patients underwent surgery and radiotherapy. To establish their influence on survival, 10 histological variables were evaluated (degree of cellularity, polymorphism, predominant cell type, nuclear atypia, mitotic index, vascular proliferation, endothelial hyperplasia, glomeruloid formations, lymphocytic infiltration, necrosis and pseudofences). Two definite levels of aggressivity were found (anaplastic astrocytoma and multiform glioblastoma) with statistically significant differences in survival (p less than 0.025). They were diagnosed on the basis of the presence or absence of necrosis. In the absence of this parameter, vascular phenomena, cellularity and nuclear atypia were found to be valid for the differentiation of the two mentioned groups.
Collapse
|
48
|
Aneiros-Cachaza J, Caracuel MD, Cámara M, Alonso J. Neuroendocrine changes in basal cell carcinoma. Acta Cytol 1988; 32:431-2. [PMID: 3376714] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
49
|
Caralps JM, Bonnin JO, Padró JM, Cámara M, Solé O, Arís A. "Shoehorn technique" for inserting Ionescu-Shiley valves in the mitral position. Tex Heart Inst J 1983; 10:53-5. [PMID: 15227154 PMCID: PMC341603] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/30/2023]
Abstract
A technique is described for safer and easier insertion of the Ionescu-Shiley valves at the mitral level by using the same principle that applies in the use of a shoehorn.
Collapse
Affiliation(s)
- J M Caralps
- Cardiac Surgery Unit, Hospital de la Santa Cruz y San Pablo, Barcelona, Spain
| | | | | | | | | | | |
Collapse
|